Your browser doesn't support javascript.
loading
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
Cheng, Xin; Li, Jing; Tanaka, Keigo; Majumder, Utpal; Milinichik, Andrew Z; Verdi, Arielle C; Maddage, Christopher J; Rybinski, Katherine A; Fernando, Shawn; Fernando, Danielle; Kuc, Megan; Furuuchi, Keiji; Fang, Frank; Uenaka, Toshimitsu; Grasso, Luigi; Albone, Earl F.
Afiliación
  • Cheng X; Department of Biochemistry Discovery, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Li J; Department of Translational Chemistry, Eisai AiM Institute, Eisai Inc., Andover, Massachusetts.
  • Tanaka K; Department of Chemistry Research, Eisai Co. Ltd., Tsukuba-Shi, Ibaraki, Japan.
  • Majumder U; Department of Discovery Chemistry, Eisai AiM Institute, Eisai Inc., Andover, Massachusetts.
  • Milinichik AZ; Department of Biochemistry Discovery, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Verdi AC; Department of Biochemistry Discovery, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Maddage CJ; Department of Preclinical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Rybinski KA; Department of Preclinical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Fernando S; Department of Bioanalytical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Fernando D; Department of Bioanalytical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Kuc M; Department of Bioanalytical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Furuuchi K; Department of Preclinical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Fang F; Department of Translational Chemistry, Eisai AiM Institute, Eisai Inc., Andover, Massachusetts.
  • Uenaka T; Department of Preclinical Development, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania.
  • Grasso L; Department of Discovery Research, Morphotek Inc., Exton, Pennsylvania.
  • Albone EF; Department of Biochemistry Discovery, Oncology Biologics Laboratories, Oncology Business Group, Eisai Inc, Exton, Pennsylvania. ealbone@morphotek.com.
Mol Cancer Ther ; 17(12): 2665-2675, 2018 12.
Article en En | MEDLINE | ID: mdl-30262588
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Receptor 1 de Folato / Anticuerpos Monoclonales Humanizados / Furanos / Cetonas / Microtúbulos / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Receptor 1 de Folato / Anticuerpos Monoclonales Humanizados / Furanos / Cetonas / Microtúbulos / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2018 Tipo del documento: Article